NASDAQ
25.03USD
-0.79 (-3.06%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.4B
P/E
—
EPS
—
Beta
2.07
52W range
8.665-27.65
Day range
24.80–26.25
Open
26.19
Prev close
25.82
Volume
772.6K
Avg volume
1.3M
Dividend
0.00
IPO
2020-10-02
https://www.fool.com/coverage/filings/2026/07/12/what-this-immunome-sale-means-a-day-before-a-big-fda-milestone/ · 7/12/2026+0.60
https://www.zacks.com/stock/news/2951708/immunome-stock-up-32-in-a-month-here-s-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-analyst_blog|price_surge_/_plunge-2951708 · 7/10/2026+1.00
https://seekingalpha.com/article/4913158-immunome-stock-varegacestat-is-the-beachhead-but-the-adc-engine-is-the-thesis · 6/9/2026+1.00
https://www.defenseworld.net/2026/04/05/max-rosett-sells-65000-shares-of-immunome-nasdaqimnm-stock.html · 4/5/2026-0.20
https://www.fool.com/coverage/filings/2026/04/04/immunome-s-chief-scientist-trimmed-his-stake-a-planned-fda-submission-tells-you-more/ · 4/4/2026-0.35
https://www.businesswire.com/news/home/20260305617846/en/Immunome-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4/ · 3/5/2026+0.10
https://www.fool.com/coverage/filings/2026/02/22/biotech-focused-fund-adds-usd49-million-to-immunome-bet-as-stock-surges-120/ · 2/22/2026+1.00
https://www.businesswire.com/news/home/20260108374499/en/Immunome-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4/ · 1/8/2026+0.10
https://www.defenseworld.net/2025/12/23/immunome-nasdaqimnm-ceo-clay-siegall-buys-7278-shares-of-stock.html · 12/23/2025+0.40
https://seekingalpha.com/article/4854145-immunome-maintaining-strong-buy-on-successful-ringside-trial-with-varegacestat · 12/17/2025+1.00
https://www.businesswire.com/news/home/20251215295131/en/Immunome-Announces-Proposed-Public-Offering-of-Common-Stock/ · 12/15/2025-0.20
https://www.businesswire.com/news/home/20251214414258/en/Immunome-to-Announce-Topline-Results-from-Phase-3-RINGSIDE-Trial-of-Varegacestat-in-Patients-with-Desmoid-Tumors/ · 12/14/2025+0.10
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
